Tocagen (TOCA) Now Covered by Analysts at Cantor Fitzgerald

Share on StockTwits

Equities research analysts at Cantor Fitzgerald assumed coverage on shares of Tocagen (NASDAQ:TOCA) in a research report issued to clients and investors on Thursday, The Fly reports. The brokerage set an “overweight” rating on the stock.

Several other research firms have also commented on TOCA. Zacks Investment Research lowered shares of Tocagen from a “buy” rating to a “hold” rating in a research report on Saturday, January 26th. B. Riley initiated coverage on shares of Tocagen in a report on Monday, December 31st. They issued a “buy” rating and a $22.00 target price for the company. Leerink Swann initiated coverage on shares of Tocagen in a report on Monday, April 15th. They issued a “market perform” rating and a $10.26 target price for the company. Robert W. Baird initiated coverage on shares of Tocagen in a report on Friday, January 18th. They issued an “outperform” rating and a $20.00 target price for the company. Finally, Svb Leerink initiated coverage on shares of Tocagen in a report on Monday, April 15th. They issued a “market perform” rating and a $11.00 target price for the company. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $18.58.

Shares of NASDAQ TOCA traded up $0.61 during midday trading on Thursday, hitting $9.13. 286,870 shares of the company’s stock traded hands, compared to its average volume of 136,104. Tocagen has a 1 year low of $6.47 and a 1 year high of $15.80. The firm has a market capitalization of $199.66 million, a P/E ratio of -3.74 and a beta of 3.50. The company has a quick ratio of 5.91, a current ratio of 5.91 and a debt-to-equity ratio of 0.45.

Tocagen (NASDAQ:TOCA) last released its quarterly earnings results on Wednesday, February 27th. The company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.35). Tocagen had a negative net margin of 271.43% and a negative return on equity of 92.56%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. As a group, equities research analysts anticipate that Tocagen will post -2.99 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in TOCA. BlackRock Inc. boosted its stake in Tocagen by 6.2% in the 4th quarter. BlackRock Inc. now owns 1,501,501 shares of the company’s stock worth $12,327,000 after purchasing an additional 88,216 shares during the period. Vanguard Group Inc. boosted its stake in Tocagen by 14.9% in the 3rd quarter. Vanguard Group Inc. now owns 787,550 shares of the company’s stock worth $12,278,000 after purchasing an additional 101,874 shares during the period. Vanguard Group Inc boosted its stake in Tocagen by 14.9% in the 3rd quarter. Vanguard Group Inc now owns 787,550 shares of the company’s stock worth $12,278,000 after purchasing an additional 101,874 shares during the period. Foresite Capital Management III LLC boosted its stake in Tocagen by 347.8% in the 4th quarter. Foresite Capital Management III LLC now owns 665,219 shares of the company’s stock worth $5,461,000 after purchasing an additional 516,667 shares during the period. Finally, Citigroup Inc. boosted its stake in Tocagen by 1,917.8% in the 4th quarter. Citigroup Inc. now owns 457,246 shares of the company’s stock worth $3,754,000 after purchasing an additional 434,585 shares during the period. 36.47% of the stock is owned by institutional investors.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Recommended Story: What defines an oversold asset?

The Fly

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Set Health Insurance Innovations Inc  Price Target at $59.00
Brokerages Set Health Insurance Innovations Inc Price Target at $59.00
JPMorgan Alerian MLP Index ETN Declares Quarterly Dividend of $0.41
JPMorgan Alerian MLP Index ETN Declares Quarterly Dividend of $0.41
Eugene A. Miller Sells 10,000 Shares of TriMas Corp  Stock
Eugene A. Miller Sells 10,000 Shares of TriMas Corp Stock
PluraCoin 1-Day Trading Volume Reaches $7.00
PluraCoin 1-Day Trading Volume Reaches $7.00
BOScoin Hits Market Cap of $7.73 Million
BOScoin Hits Market Cap of $7.73 Million
MARKS & SPENCER/S  Given News Impact Rating of -3.79
MARKS & SPENCER/S Given News Impact Rating of -3.79


© 2006-2019 Ticker Report